Summary: Study reports elevated amyloid plaque are not just a risk factor for Alzheimer’s, but part of the disease and the earliest precursor before symptoms appear.
Clusters of a sticky protein — amyloid plaque — found in the brain signal mental decline years before symptoms appear, a new study finds.
Older adults with elevated levels of brain-clogging plaques — but otherwise normal cognition — experience faster mental decline suggestive of Alzheimer’s disease, according to a new study led by the Keck School of Medicine of USC that looked at 10 years of data.
Just about all researchers see amyloid plaques as a risk factor for Alzheimer’s.
However, this study presents the toxic, sticky protein as part of the disease — the earliest precursor before symptoms arise.
“To have the greatest impact on the disease, we need to intervene against amyloid, the basic molecular cause, as early as possible,” said Paul Aisen, senior author of the study and director of the USC Alzheimer’s Therapeutic Research Institute (ATRI) at the Keck School of Medicine. “This study is a significant step toward the idea that elevated amyloid levels are an early stage of Alzheimer’s, an appropriate stage for anti-amyloid therapy.”
Notably, the incubation period with elevated amyloid plaques — the asymptomatic stage — can last longer than the dementia stage.
“This study is trying to support the concept that the disease starts before symptoms, which lays the groundwork for conducting early interventions,” said Michael Donohue, lead author of the study and an associate professor of neurology at USC ATRI.
The researchers likened amyloid plaque in the brain to cholesterol in the blood. Both are warning signs with few outward manifestations until a catastrophic event occurs. Treating the symptoms can fend off the resulting malady — Alzheimer’s or a heart attack — the effects of which may be irreversible and too late to treat.
“We’ve learned that intervening before the heart attack is a much more powerful approach to treating the problem,” Donohue said.
Aisen, Donohue and others hope that removing amyloid at the preclinical stage will slow the onset of Alzheimer’s or even stop it.
The amyloid problem
One in three people over 65 have elevated amyloid in the brain, Aisen noted, and the study indicates that most people with elevated amyloid will progress to symptomatic Alzheimer’s within 10 years.
If Alzheimer’s prevalence estimates were to include this “preclinical stage” before symptoms arise, the number of those affected would more than double from the current estimate of 5.4 million Americans, the study stated.
Published in The Journal of the American Medical Association on June 13, the study uses 10 years of data from the Alzheimer’s Disease Neuroimaging Initiative, an exploration of the biomarkers that presage Alzheimer’s. USC ATRI is the coordinating center of this North American investigation. Aisen co-directs its clinical core.
USC plays a leading role in the only two anti-amyloid studies focused on the early, preclinical stage of sporadic Alzheimer’s: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the A4 Study) and the EARLY Trial, Aisen said.
“We need more studies looking at people before they have Alzheimer’s symptoms,” Aisen said. “The reason many promising drug treatments have failed to date is because they intervened at the end-stage of the disease when it’s too late. The time to intervene is when the brain is still functioning well — when people are asymptomatic.”
Although elevated amyloid is associated with subsequent cognitive decline, the study did not prove a causal relationship.
For years, researchers have acknowledged age is the biggest risk factor when it comes to Alzheimer’s. For more than 90 percent of people with Alzheimer’s, symptoms do not appear until after age 60, according to the Centers for Disease Control and Prevention.
In 2014, about 46 million adults living in the United States — 15 percent of the population — were 65 or older. By 2050, that number is expected to expand to 88 million or 22 percent of the population.
The tipping point
Researchers measured amyloid levels in 445 cognitively normal people in the United States and Canada via cerebrospinal fluid taps or positron emission tomography (PET) scans: 242 had normal amyloid levels and 202 had elevated amyloid levels. Cognitive tests were performed on the participants, who had an average age of 74.
Although the observation period lasted 10 years, each participant, on average, was observed for three years. The maximum follow-up was 10 years.
The elevated amyloid group was older and less educated. Additionally, a larger proportion of this group carried at least one copy of the ApoE4 gene, which increases the odds that someone will develop Alzheimer’s.
Based on global cognition scores, at the four-year mark, 32 percent of people with elevated amyloid had developed symptoms consistent with the early stage of Alzheimer’s disease. In comparison, only 15 percent of participants with normal amyloid showed a substantial decline in cognition.
Analyzing a smaller sample size at year 10, researchers noted that 88 percent of people with elevated amyloid were projected to show significant mental decline based on global cognitive tests. Comparatively, just 29 percent of people with normal amyloid showed cognitive decline.
Alzheimer’s disease research worldwide
Alzheimer’s was recently a disease that could be diagnosed only after death with an autopsy.
Aisen and the researchers at USC ATRI have developed ways to identify early signs of Alzheimer’s by creating a set of cognitive tests called the Preclinical Alzheimer Cognitive Composite. This battery of tests and variations of it are widely used to detect Alzheimer’s before dementia symptoms emerge, Aisen said.
“Our outcome measures are becoming the standard for early Alzheimer’s disease intervention studies,” Aisen said. “Drug companies will not invest in early intervention studies without a regulatory pathway forward. ATRI and USC are building a framework for drug development in Alzheimer’s disease.”
As a research institution devoted to promoting health across the life span, USC has more than 70 researchers dedicated to the prevention, treatment and potential cure of Alzheimer’s disease.
About this neuroscience research article
Reisa Sperling at Harvard Medical School, Ronald Petersen at the Mayo Clinic, Chung-Kai Sun at USC ATRI and Michael Weiner at the University of California, San Francisco also contributed to this study.
Funding: This work was supported by Biomarkers Across Neurodegenerative Disease, Alzheimer’s Association, Michael J. Fox Foundation, Weston Brain Institute, Alzheimer’s Disease Neuroimaging Initiative, National Institutes of Health.
Source: Zen Vuong – USC Image Source: NeuroscienceNews.com image is in the public domain. Original Research: Abstract for “Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons” by Michael C. Donohue, PhD; Reisa A. Sperling, MD, MMSc; Ronald Petersen, MD, PhD; Chung-Kai Sun, MS; Michael W. Weiner, MD; Paul S. Aisen, MD; for the Alzheimer’s Disease Neuroimaging Initiative in JAMA. Published online June 13 2017 doi:10.1001/jama.2017.6669
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]USC “Researchers Discover What May Be the Earliest Stage of Alzheimer’s.” NeuroscienceNews. NeuroscienceNews, 13 June 2017. <https://neurosciencenews.com/early-alzheimers-6901/>.[/cbtab][cbtab title=”APA”]USC (2017, June 13). Researchers Discover What May Be the Earliest Stage of Alzheimer’s. NeuroscienceNew. Retrieved June 13, 2017 from https://neurosciencenews.com/early-alzheimers-6901/[/cbtab][cbtab title=”Chicago”]USC “Researchers Discover What May Be the Earliest Stage of Alzheimer’s.” https://neurosciencenews.com/early-alzheimers-6901/ (accessed June 13, 2017).[/cbtab][/cbtabs]
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
Importance Among cognitively normal individuals, elevated brain amyloid (defined by cerebrospinal fluid assays or positron emission tomography regional summaries) can be related to risk for later Alzheimer-related cognitive decline. Objective To characterize and quantify the risk for Alzheimer-related cognitive decline among cognitively normal individuals with elevated brain amyloid.
Design, Setting, and Participants Exploratory analyses were conducted with longitudinal cognitive and biomarker data from 445 cognitively normal individuals in the United States and Canada. Participants were observed from August 23, 2005, to June 7, 2016, for a median of 3.1 years (interquartile range, 2.0-4.2 years; maximum follow-up, 10.3 years) as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Exposures Individuals were classified at baseline as having normal (n = 243) or elevated (n = 202) brain amyloid using positron emission tomography amyloid imaging or a cerebrospinal fluid assay of amyloid β. Main Outcomes and Measures Outcomes included scores on the Preclinical Alzheimer Cognitive Composite (PACC; a sum of 4 baseline standardized z scores, which decreases with worse performance), Mini-Mental State Examination (MMSE; 0 [worst] to 30 [best] points), Clinical Dementia Rating Sum of Boxes (CDR–Sum of Boxes; 0 [best] to 18 [worst] points), and Logical Memory Delayed Recall (0 [worst] to 25 [best] story units).
Results Among the 445 participants (243 with normal amyloid, 202 with elevated amyloid), mean (SD) age was 74.0 (5.9) years, mean education was 16.4 (2.7) years, and 52% were women. The mean score for PACC at baseline was 0.00 (2.60); for MMSE, 29.0 (1.2); for CDR–Sum of Boxes, 0.04 (0.14); and for Logical Memory Delayed Recall, 13.1 (3.3). Compared with the group with normal amyloid, those with elevated amyloid had worse mean scores at 4 years on the PACC (mean difference, 1.51 points [95% CI, 0.94-2.10]; P < .001), MMSE (mean difference, 0.56 points [95% CI, 0.32-0.80]; P < .001), and CDR–Sum of Boxes (mean difference, 0.23 points [95% CI, 0.08-0.38]; P = .002). For Logical Memory Delayed Recall, between-group score was not statistically significant at 4 years (mean difference, 0.73 story units [95% CI, −0.02 to 1.48]; P = .056).
Conclusions and Relevance Exploratory analyses of a cognitively normal cohort followed up for a median of 3.1 years suggest that elevation in baseline brain amyloid level, compared with normal brain amyloid level, was associated with higher likelihood of cognitive decline, although the findings are of uncertain clinical significance. Further research is needed to assess the clinical importance of these differences and measure longer-term associations.
“Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons” by Michael C. Donohue, PhD; Reisa A. Sperling, MD, MMSc; Ronald Petersen, MD, PhD; Chung-Kai Sun, MS; Michael W. Weiner, MD; Paul S. Aisen, MD; for the Alzheimer’s Disease Neuroimaging Initiative in JAMA. Published online June 13 2017 doi:10.1001/jama.2017.6669